谁对参与卒中临床试验说「不」以及为什么:来自温哥华卒中项目的观察性研究
该观察性研究回顾性及前瞻性分析了温哥华卒中项目四个试验的筛查日志,共235例患者被邀请知情同意。手术试验(59%)和抗血栓试验(53%)的拒绝率高于非随机外部监测设备研究(13%)(p < 0.001)。女性拒绝率高于男性(48% vs 33%),校正年龄和试验干预后女性仍更不易同意(OR 0.46,95% CI 0.26-0.82,p = 0.009)。
要点
- 手术试验和抗血栓试验的拒绝率分别为59%和53%,高于设备研究的13%(p < 0.001)。
- 手术试验拒绝主要因希望确定接受特定干预(39%),抗血栓试验主要因担心研究药物潜在副作用(41%)。
- 女性拒绝率48%高于男性33%,校正后OR 0.46(95% CI 0.26-0.82,p = 0.009)。
核心结论
- 药物安全性担忧、随机化和不感兴趣是拒绝参加卒中试验的主要原因,且同意率存在性别差异。
- 更好地理解患者拒绝参与卒中试验的原因可能有助于制定未来以患者为导向的沟通策略以提高入组率。
- 需要进一步研究以更好地理解同意率性别差异背后的原因。
研究设计与样本
- 观察性研究,评估温哥华卒中项目符合条件并被邀请参与临床试验的患者拒绝提供知情同意的原因。
- 回顾性审查2015年6月至2017年4月四个正在招募的试验的筛查日志:三项随机试验(NAVIGATE-ESUS、DATAS-II、CREST-2)和一项观察性非随机试验(PROPHECY)。
- 随后于2017年5月至2018年3月使用前瞻性结构化病例报告表进行筛查。
- 共235例患者(43%女性)被邀请同意。
- 使用描述性统计、卡方检验、Fisher精确检验和t检验,并用多变量逻辑回归模型(包括年龄和试验干预作为协变量)检查性别对拒绝可能性的影响。
主要发现
- 手术试验拒绝率为59%,抗血栓试验为53%,非随机外部监测设备研究为13%(p < 0.001)。
- 手术试验拒绝主要因希望确定接受特定干预(39%),其中多数患者希望手术。
- 抗血栓试验拒绝主要因担心研究药物潜在副作用(41%);设备试验拒绝主要因不感兴趣(46%)。
- 女性拒绝参与率高于男性(48% vs 33%)。
- 校正年龄和试验干预后,女性仍比男性更不易同意(OR 0.46,95% CI 0.26-0.82,p = 0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以更好地理解同意率性别差异背后的原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Successful stroke trials require adequate recruitment. In this observational study, we assessed reasons for refusal to provide informed consent in eligible patients approached for clinical trial participation at the Vancouver Stroke Program. METHODS: We assessed screening logs from four trials that were actively recruiting at our center: three randomized trials, two of which investigated different antithrombotic strategies for secondary prevention (NAVIGATE-ESUS, NCT02313909 12/2014; DATAS-II, NCT02295826 11/2014) and one that investigated surgery plus medical management versus medical management alone for primary prevention (CREST-2, NCT02089217 03/2014). The fourth study was observational and non-randomized; all participants received an external monitoring device (PROPHECY, NCT03712865 10/2018). Screening logs from June 2015 to April 2017 were reviewed retrospectively. Subsequently, we used a prospective structured case report form for screening (May 2017-March 2018). We assessed and compared refusal rates between trials, demographics of those refusing consent, and their reasons for doing so. We used descriptive statistics, chi-square and Fisher's exact tests as appropriate for non-parametric data, and t-tests for parametric data. We examined likelihood of refusal by sex using multivariable logistic regression models including age and trial intervention as co-variables. RESULTS: A total of 235 patients (43% women) were approached for consent. More patients refused the surgical (59%) and antithrombotic trials (53%) compared with the non-randomized external monitoring device study (13%) (p < 0.001). Surgical trial refusals were primarily due to a desire for certainty in receiving a particular intervention (39%), with the majority of those patients wanting surgery. Refusals for the antithrombotic trials were mainly due to concerns with the potential side effects of the study drug (41%); refusals in the device trial were mainly due to disinterest (46%). Women refused participation more often than men (48% vs 33%). Women remained less likely to consent than men, even after adjustment for age and trial intervention (OR 0.46, 95% CI 0.26-0.82, p = 0.009). CONCLUSIONS: Concern surrounding drug safety, randomization, and disinterest were the chief deterrents to enrolment; there were also differences in rates of consent by gender. A better understanding of why patients refuse participation in stroke trials may help to develop future patient-directed communication strategies to improve enrolment. Further research is required to better understand the reasons underlying gender disparities in consent rates.
引用
- O'Neill ZR, Deptuck HM, Quong L, et al. Who says "no" to participating in stroke clinical trials and why: an observational study from the Vancouver Stroke Program. Trials. 2019. PMID: 31151483. doi:10.1186/s13063-019-3434-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。